Company Encyclopedia
View More
name
CLOVER BIO-B
02197.HK
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, the company sells biopharmaceutical drugs.
1.309 T
02197.HKMarket value -Rank by Market Cap -/-

Financial Score

10/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking31/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE71.65%A
    • Profit Margin-1756.85%E
    • Gross Margin101.17%A
  • Growth ScoreB
    • Revenue YoY79.43%A
    • Net Profit YoY-3.02%C
    • Total Assets YoY-66.32%E
    • Net Assets YoY-108.68%E
  • Cash ScoreB
    • Cash Flow Margin-5.69%D
    • OCF YoY79.43%A
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreE
    • Gearing Ratio387.13%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hong Kong stock pharmaceutical stocks strengthened, with ASCLETIS-B rising over 9%, CLOVER BIO-B rising over 8%, WUXI BIO rising nearly 7%, and CARSGEN-B rising over 5%

    Wallstreetcn·
    HK
    02197
    +0.74%
    US
    WXXWY
    +0.12%
    HK
    02269
    +0.06%
    Wallstreetcn·
    HK
    02197
    +0.74%
    US
    WXXWY
    +0.12%
    HK
    02269
    +0.06%

    Hong Kong Stock Movement: CLOVER BIO-B surged 17.87%, with active capital inflow attracting market attention

    CLOVER BIO-B rose 17.87%; BeiGene rose 7.53%, with a transaction volume of HKD 1.839 billion; 3SBio rose 9.52%, with a transaction volume of HKD 1.69 billion; Innovent Biologics rose 6.48%, with a transaction volume of HKD 1.534 billion; CanSino Biologics rose 3.57%, with a market value of HKD 112.2 billion

    HK Stock Movers Tracker·
    HK
    02197
    +0.74%
    HK Stock Movers Tracker·
    HK
    02197
    +0.74%

    CLOVER BIO appoints Nicholas Jackson as President of Global R&D and Strategic Alliances

    CLOVER BIO announced the appointment of Nicholas Jackson as President of Global R&D and Strategic Alliances. Nicholas Jackson will work closely with the company's CEO Liang Guo to accelerate the development of CLOVER BIO's combined vaccine candidate RSV+hMPV±PIV3

    Zhitong·
    HK
    02197
    +0.74%
    Zhitong·
    HK
    02197
    +0.74%

    Hong Kong stock movement: CLOVER BIO-B surged nearly 14%! Positive early clinical data for the respiratory combined vaccine, development process accelerated

    CLOVER BIO-B rose 13.66%; WuXi AppTec-B surged 21.61%, with a transaction volume of HKD 1.813 billion; InnoCare Pharma-B rose 4.50%, with a transaction volume of HKD 1.041 billion; Innovent Biologics fell 1.97%, with a transaction volume of HKD 780 million; BeiGene fell 2.16%, with a market value of HKD 286.3 billion

    HK Stock Movers Tracker·
    HK
    02197
    +0.74%
    HK Stock Movers Tracker·
    HK
    02197
    +0.74%

    Hong Kong Stock Movement: CLOVER BIO-B fell 16.67%

    CLOVER BIO-B fell 16.67%; InnoCare Pharma-B rose 0.33%, with a transaction volume of HKD 3.297 billion; Innovent Biologics rose 2.03%, with a transaction volume of HKD 1.09 billion; CanSino Biologics rose 0.91%, with a transaction volume of HKD 887 million; BeiGene rose 1.08%, with a market capitalization of HKD 289.3 billion

    HK Stock Movers Tracker·
    HK
    02197
    +0.74%
    HK Stock Movers Tracker·
    HK
    02197
    +0.74%
    © 2025 Longbridge｜Disclaimer